• Significant expansion of VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore
• Focus on advancing liquid controlled-release drug products and optimising therapeutic outcomes
• Supported by the Singapore Economic Development Board (EDB) through a five-year funded plan

CLINUVEL Pharmaceuticals Ltd today announced a significant expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This strategic five-year investment will integrate comprehensive formulation and analytical sciences, focusing on advancing liquid controlled-release drug products designed to optimise therapeutic outcomes for patients. The expansion is supported by the Singapore Economic Development Board (EDB) and is a key pillar in CLINUVEL's strategy of vertical integration and innovation in peptide-based medicine. Since its founding in 2014, the VALLAURIX site has evolved, with the current ISO9001-certified centre opening in 2020 and receiving extensive upgrades in 2022. The new expansion will further broaden its formulation and analytical capabilities, with full commissioning and certification targeted for FY2028. CLINUVEL's global team is spearheading the expansion, with plans to gradually increase specialist headcount in Singapore over the next five years. This growth is made possible through a strengthened economic partnership with the EDB, whose continued investment facilitates the addition of technical expertise and state-of-the-art capabilities. The expansion process will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted, while preparing CLINUVEL to translate its research into tangible advanced therapies.

This strategic expansion underscores CLINUVEL's commitment to leveraging Singapore's vibrant biotech ecosystem to address complex therapeutic challenges and deliver the next wave of peptide-based medicines.